|
WO2021074842A1
|
|
Improved process for the preparation of diroximel fumarate and solid forms thereof
|
|
WO2021070123A1
|
|
Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
|
|
WO2021070124A1
|
|
Alternate processes for the preparation of omecamtiv mecarbil
|
|
WO2021053578A1
|
|
Improved purification processes for liraglutide
|
|
WO2021053542A1
|
|
Pharmaceutical compositions for obesity management
|
|
WO2021044350A1
|
|
Solid forms of encequidar mesylate and processes thereof
|
|
WO2021033098A1
|
|
Process for the preparation of apalutamide
|
|
WO2020261195A1
|
|
Substantially pure venetoclax and amorphous venetoclax in a free drug particulate form
|
|
WO2020240375A1
|
|
Improved process for the preparation of elagolix and its intermediates
|
|
WO2020230094A1
|
|
Amorphous and crystalline forms of relugolix
|
|
WO2020217190A1
|
|
Process for the purification of roxadustat
|
|
WO2020208592A1
|
|
Process for preparation of erdafitinib, its purification and amorphous solid dispersion
|
|
WO2020202096A1
|
|
Amorphous filgotinib maleate, its solid dispersion and processes thereof
|
|
WO2020194152A1
|
|
Process for preparation of bempedoic acid
|
|
WO2020170185A1
|
|
Substantially pure lanreotide or its salt & process thereof
|
|
WO2020161632A1
|
|
Crystalline solid forms of siponimod
|
|
WO2020104955A1
|
|
Pharmaceutical compositions of acotiamide and proton pump inhibitor
|
|
WO2020075024A1
|
|
Process for preparation of memantine
|
|
WO2020016847A2
|
|
Purification process for preparation of eribulin and intermediates thereof
|
|
WO2020008382A1
|
|
Process for preparation of eribulin and intermediates thereof
|
